Abbott Laboratories ( ABT ) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ABT-450/r, ABT-267, ABT-333 and ribavirin for the treatment of
See the article here:
Abbott Reports Encouraging HCV Data – Analyst Blog